Scilex Holding Company Reports Q1 2026 Financial Results with $8.6M Revenue and Increased Losses

Scilex Holding Company reported its financial results for the first quarter of 2026, revealing a net revenue of $8.6 million, a significant increase from $5.0 million in the same period last year. This growth was primarily driven by a $1.1 million rise in sales of its flagship product, ZTlido, and a $2.4 million contribution from Vivasor contract revenue. However, the company also faced increased operating costs, with total expenses rising to $40.8 million from $32.9 million year-over-year, leading to a loss from operations of $32.2 million compared to $27.9 million in the prior year.

The company's financial position showed a decline in cash and cash equivalents, which fell to approximately $3.4 million from $4.9 million at the end of 2025. Scilex's accumulated deficit increased to $965.1 million, reflecting ongoing investments in research and development, particularly for its product candidates SEMDEXA, SP-103, and SP-104. The company has indicated that it will require substantial additional funding to support its operations and growth strategy, which may include equity offerings, debt financings, and collaborations.

In terms of strategic developments, Scilex has been active in expanding its product portfolio. The company launched ELYXYB in the U.S. in April 2023 and GLOPERBA in June 2024, both of which are FDA-approved treatments. Additionally, Scilex is developing three product candidates, with SEMDEXA currently in a Phase 3 study. The company has also adopted a cryptocurrency treasury strategy, acquiring Bitcoin and other digital assets as part of its long-term financial strategy.

Operationally, Scilex reported a customer concentration risk, with four customers generating 95% of its revenue for the quarter. The company continues to rely on a limited number of suppliers for its products, which poses additional risks. As of March 31, 2026, Scilex had a total of 8,491,267 shares of common stock outstanding and remains classified as a smaller reporting company and an emerging growth company under SEC regulations.

Looking ahead, Scilex's management has expressed concerns about its ability to continue as a going concern, given its negative working capital of $459.8 million and ongoing losses. The company plans to pursue various funding avenues to support its operations and product commercialization efforts, but acknowledges that its future success is contingent on the successful launch and market acceptance of its products.